ERRATUM

Erratum to Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA

Kenan Zhang1, Xing Liu2, Guanzhang Li1,3, Xin Chang4, Shouwei Li4, Jing Chen1, Zheng Zhao3, Jiguang Wang5,6,7, Tao Jiang1,3, Ruichao Chai1,2,5

1Department of Molecular Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China; 2Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China; 3Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 4Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China; 5Division of Life Science and State Key Laboratory of Molecular Neuroscience, Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR 999077, China; 6Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR 999077, China; 7HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen 518057, China

In the published version of Figure 2, an error appeared in Figure 2C on page 1468. In Figure 2C, the Kaplan-Meier estimation of the overall survival of patients with recurrent DG classified according to molecular subtypes was mistakenly covered by the curves of patients with primary DGs during the figure layout process, while the number statistic under the figure is correct. Figure 2C has been updated to correct this mistake. The error does not affect the conclusions of this article. We apologize for the error and for any confusion that it might have caused.

Reference
